CancerX shared on LinkedIn:
“Calling oncology founders: The 2027 CancerX Accelerator is open (deadline Oct 1)
Applications are now open for the CancerX Accelerator 2027 Cohort, a program designed to connect early-stage digital health startups with leading health systems, payers, investors, and industry partners to help accelerate adoption and real-world impact.
Innovation Focus Areas for CancerX 2027 Accelerator:
- Increasing Access to Clinical Trials & Research: Optimizing the end-to-end process of clinical research by supporting sites in pinpointing the most suitable opportunities, driving provider engagement, and streamlining operations to enroll patients, foster greater trust, and promote inclusive, equitable enrollment.
- Increasing Access to Quality Cancer Care, Everywhere: Improving patient outcomes with novel care delivery models by providing access to essential and timely information, engaging educational resources, and precision diagnostic and monitoring tools, regardless of location.
- Increasing Access to Smarter Care Operations: Streamlining system and administrative complexities to ease operational challenges such as targeted patient outreach, guideline concordance, and the development of an operational data backbone, enabling our workforce to focus their time where it matters most: with patients and their families.
As selected companies, the 2027 CancerX Accelerator provides:
- Champions like Advocate Health, Moffitt Cancer Center, AstraZeneca, Johnson & Johnson, Rush University, Novartis, Elevance Health, Oncology Ventures, Flare Capital, and more engage before you’re accepted.
- Zero equity. No application fee.
- On average, you’ll generate 1–3 deal opportunities and work directly with at least 2 champions.
- Guidance from 2+ dedicated mentors (digital health and oncology experts) plus 60+ hours of go-to-market and pitch coaching for each of our startups.
If you’re building innovative solutions for cancer care, now is the time to apply.
Apply today by creating a Constellation account here.”
Other articles from CancerX on OncoDaily.